180 related articles for article (PubMed ID: 6508821)
21. The overall synthesis of L-5,6-dihydroorotate by multienzymatic protein pyr1-3 from hamster cells. Kinetic studies, substrate channeling, and the effects of inhibitors.
Christopherson RI; Jones ME
J Biol Chem; 1980 Dec; 255(23):11381-95. PubMed ID: 6108323
[TBL] [Abstract][Full Text] [Related]
22. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Ardalan B; Jayaram HN; Johnson RK
Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
[TBL] [Abstract][Full Text] [Related]
23. A 70-amino acid zinc-binding polypeptide fragment from the regulatory chain of aspartate transcarbamoylase causes marked changes in the kinetic mechanism of the catalytic trimer.
Zhou BB; Waldrop GL; Lum L; Schachman HK
Protein Sci; 1994 Jun; 3(6):967-74. PubMed ID: 8069226
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
Johnson RK; Inouye T; Goldin A; Stark GR
Cancer Res; 1976 Aug; 36(8):2720-5. PubMed ID: 1064466
[TBL] [Abstract][Full Text] [Related]
25. The binding of N-(phosphonacetyl)-L-aspartate to aspartate carbamoyltransferase of Escherichia coli.
Volź KW; Krause KL; Lipscomb WN
Biochem Biophys Res Commun; 1986 Apr; 136(2):822-6. PubMed ID: 3518720
[TBL] [Abstract][Full Text] [Related]
26. Homotropic effects in aspartate transcarbamoylase. What happens when the enzyme binds a single molecule of the bisubstrate analog N-phosphonacetyl-L-aspartate?
Foote J; Schachman HK
J Mol Biol; 1985 Nov; 186(1):175-84. PubMed ID: 3908690
[TBL] [Abstract][Full Text] [Related]
27. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
Moore EC
Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
Loo TL; Friedman J; Moore EC; Valdivieso M; Marti JR; Stewart D
Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907
[TBL] [Abstract][Full Text] [Related]
29. Inhibition by N-(phosphonacetyl)-L-aspartate of Ehrlich ascites tumour growth and glucose transport.
Leung SW; Fung KP; Choy YM; Lee CY
Cancer Lett; 1984 Jun; 23(2):183-8. PubMed ID: 6744243
[TBL] [Abstract][Full Text] [Related]
30. Overproduction of the first three enzymes of pyrimidine nucleotide biosynthesis in Drosophila cells resistant to N-phosphonacetyl-L-aspartate.
Laval M; Azou Y; Giorgi D; Rosset R
Exp Cell Res; 1986 Apr; 163(2):381-95. PubMed ID: 2869965
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
[TBL] [Abstract][Full Text] [Related]
32. PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
Yang JL; Fernandes DJ; Wheeler KT; Capizzi RL
Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1073-9. PubMed ID: 8600090
[TBL] [Abstract][Full Text] [Related]
33. Multiple mechanisms of N-phosphonacetyl-L-aspartate resistance in human cell lines: carbamyl-P synthetase/aspartate transcarbamylase/dihydro-orotase gene amplification is frequent only when chromosome 2 is rearranged.
Smith KA; Chernova OB; Groves RP; Stark MB; Martínez JL; Davidson JN; Trent JM; Patterson TE; Agarwal A; Duncan P; Agarwal ML; Stark GR
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1816-21. PubMed ID: 9050862
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
Erlichman C; Vidgen D
Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
Miller AA; Moore EC; Hurlbert RB; Benvenuto JA; Loo TL
Cancer Res; 1983 Jun; 43(6):2565-70. PubMed ID: 6189583
[TBL] [Abstract][Full Text] [Related]
36. Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man.
Lankelma J; Penders PG; Leyva A; Kleeberg UR; Kenny JB; Bramwell V; McVie JG; Pinedo HM
Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1199-204. PubMed ID: 7199467
[No Abstract] [Full Text] [Related]
37. Kinetic parameters of aspartate transcarbamylase in human normal and tumoral cell lines.
Baillon J; Guichard M; Malaise EP; Hervé G
Cancer Res; 1983 May; 43(5):2277-82. PubMed ID: 6831451
[TBL] [Abstract][Full Text] [Related]
38. Stable mutants of mammalian cells that overproduce the first three enzymes of pyrimidine nucleotide biosynthesis.
Kempe TD; Swyryd EA; Bruist M; Stark GR
Cell; 1976 Dec; 9(4 Pt 1):541-50. PubMed ID: 12870
[TBL] [Abstract][Full Text] [Related]
39. Binding of bisubstrate analog promotes large structural changes in the unregulated catalytic trimer of aspartate transcarbamoylase: implications for allosteric regulation.
Endrizzi JA; Beernink PT; Alber T; Schachman HK
Proc Natl Acad Sci U S A; 2000 May; 97(10):5077-82. PubMed ID: 10805770
[TBL] [Abstract][Full Text] [Related]
40. A single amino acid substitution in the active site of Escherichia coli aspartate transcarbamoylase prevents the allosteric transition.
Stieglitz KA; Pastra-Landis SC; Xia J; Tsuruta H; Kantrowitz ER
J Mol Biol; 2005 Jun; 349(2):413-23. PubMed ID: 15890205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
